Aiforia Technologies Plc – Managers’ Transactions – Veli-Matti Parkkonen

Aiforia Technologies Plc, COMPANY RELEASE, MANAGERS’ TRANSACTIONS January 20, 2026 02:15 p.m. EET

Aiforia Technologies Plc has received a notification from Veli-Matti Parkkonen, Aiforia Technologies Plc's Chief Financial Officer, of a transaction made with Aiforia Technologies Plc’s financial instrument, according to the Article 19 of EU Market Abuse Regulation.

Detailed information about the transaction is given here under.

____________________________________________

Aiforia Technologies Oyj - Managers' Transactions

____________________________________________

Person subject to the notification requirement

Name: Veli-Matti Parkkonen

Position: Chief Financial Officer

Issuer: Aiforia Technologies Oyj

LEI: 743700TJRVBX7420Y723

Notification type: INITIAL NOTIFICATION

Reference number: 139199/6/4

____________________________________________

Transaction date: 2026-01-19

Outside a trading venue

Instrument type: DERIVATIVE

Name of the instrument: Aiforia technologies Oyj Optio ohjelma 2021 IV

Nature of transaction: EXERCISE OF A STOCK OPTION

Transaction details

(1): Volume: 20000 Unit price: 1.3724 EUR

Aggregated transactions (1):

Volume: 20000 Volume weighted average price: 1.3724 EUR

Further inquiries 
Veli-Matti Parkkonen, CFO, Aiforia Technologies Plc,
tel. +358405009878
https://investors.aiforia.com/

Certified Adviser 
UB Corporate Finance Ltd
ubcf@unitedbankers.fi

About Aiforia 

Aiforia is a trusted provider of deep learning artificial intelligence (AI) solutions for pathology. Aiforia delivers advanced software solutions that elevate diagnostic capabilities in image analysis, empowering remarkable medical discoveries both today and in the future. With thousands of AI models developed for research use and several diagnostic solutions deployed, Aiforia is making a significant impact on pathology and healthcare. In Europe, Aiforia is the leading provider of CE-IVD marked AI-powered solutions for digital pathology.

Founded in 2013, Aiforia is a publicly traded company with a global presence and thousands of users worldwide. Headquartered in Helsinki, Finland, the company also operates subsidiaries in the United States and France, and maintains a network of local representatives across Europe and North America. Aiforia’s diverse team includes experienced AI and software developers, pathologists, medical scientists, and a dedicated commercial team. Together, they are transforming pathology through AI, enabling better care for every patient. 

Find out more at www.aiforia.com